Connor Clark & Lunn Investment Management Ltd. Invests $26.48 Million in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Connor Clark & Lunn Investment Management acquired 42,465 Regeneron shares worth approximately $26.48 million in the second quarter. Institutional investors and hedge funds collectively own 83.31% of REGN.
• Analysts maintain a generally positive outlook, with 16 Buy ratings and 10 Holds producing a consensus “Moderate Buy” rating and an average price target of $801.70.
• Regeneron exceeded quarterly expectations, reporting $14.29 in earnings per share and $4.29 billion in revenue, up 16.7% year over year. The company also declared a quarterly dividend of $0.94 per share.

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 42,465 shares of the biopharmaceutical company's stock, valued at approximately $26,479,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. Finally, Trust Co. of Vermont acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $29,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on REGN shares. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. HSBC reduced their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating for the company in a report on Monday, July 6th. Cantor Fitzgerald lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Finally, Truist Financial upped their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Sixteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $801.70.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the firm's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares of the company's stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,400 shares of company stock valued at $1,090,030. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.7%

NASDAQ:REGN opened at $828.50 on Tuesday. The company has a market cap of $85.30 billion, a PE ratio of 20.48, a P/E/G ratio of 1.42 and a beta of 0.22. The business's 50 day moving average is $701.36 and its two-hundred day moving average is $716.94. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the business earned $12.81 EPS. The business's quarterly revenue was up 16.7% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source